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ABSTRAK 
Latar Belakang 
Serum urik asid adalah produk pecahan akhir katabolisma purin pada manusia. Ia adalah satu 
antioksidan yang kuat, yang menyebabkan tekanan oksidatif pada sel-sel vaskular endothelial, 
dengan itu mengalakkan perkembangan penyakit yang berkaitan dengan kencing manis. 
Terdapat pelbagai bukti epidemiologi dan eksperimen yang menunjukkan bahawa serum urik 
asid memainkan peranan dalam etiologi kencing manis jenis 2. Kami telah menjalankan kajian 
keratan rentas mengaitkan ketebalan lapisan saraf retina mata (LSRM) dan ketebalan makula 
dengan serum urik asid di kalangan pesakit kencing manis jenis 2 yang tiada diabetik retinopati 
dan dengan diabetik retinopati tidak proliferasi (DRTP). 
 
Metodologi 
Satu kajian keratan rentas telah dijalankan di Kelinik Mata, Hospital Universiti Sains Malaysia, 
Kelantan antara tempoh Ogos 2013 hingga Julai 2015 melibatkan pesakit diabetes jenis 2 yang 
tiada diabetik retinopati dan dengan DRTP. Semua pesakit telah menjalani ujian pengukuran 
ketebalan LSRM dan ketebalan makula menggunakan mesin Spectralis Domain Heidelberg 
optikal koherens tomografi. Sebanyak 6 mls darah telah diambil daripada pesakit untuk ujian 
serum urik asid dan HbA1c.  
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Keputusan  
Seramai 180 pesakit kencing manis telah terlibat  (tiada diabetik retinopati: 90 pesakit dan 
DRTP: 90 pesakit) dalam kajian ini. Tahap purata serum urik asid untuk kedua-dua kumpulan 
berada dalam julat normal dan tiada perbezaan yang signifikan. Tahap purata serum urik asid 
untuk kedua-dua jantina yang tiada diabetik retinopati adalah tinggi yang signifikan berbanding 
dengan mereka yang DRTP (p = 0.004 masing-masing). Purata serum urik asid adalah lebih 
tinggi yang signifikan dalam pesakit dengan HbA1c <6.5% (p <0.031). Pesakit dalam 
kumpulan NPDR mempunyai ketebalan LSRM dan makula yang lebih tebal berbanding 
dengan pesakit dalam kumpulan yang tiada diabetik retinopati (p = 0.038). Walau 
bagaimanapun, hanya ketebalan LSRM dalam kuadran temporal dan ketebalan makula dalam 
sub-bidang luar superior, sub-bidang luar inferior dan sub-bidang luar temporal  menunjukkan 
perbezaan yang signifikan (p = 0.038, p = 0.004, 0.033 dan <0.001 masing-masing). Di dapati 
korelasi yang lemah di antara ketebalan RNFL dan makula dengan serum urik asid di kalangan 
pesakit di kedua-dua kumpulan.  
 
Kesimpulan  
Serum urik asid menunjukkan korelasi yang lemah dengan LSRM dan ketebalan makula di 
kalangan pesakit kencing manis jenis 2 yang tiada retinopati diabetik dan DRTP . 
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ABSTRACT 
Background 
Serum uric acid is a final breakdown product of purine catabolism in humans. It’s a potent 
antioxidant, that induces oxidative stress on the vascular endothelial cells, thus mediating 
progression of diabetic related diseases. Various epidemiological and experimental evidence 
suggest that uric acid has a role in the etiology of type 2 diabetes mellitus. We conducted a 
cross-sectional study to evaluate the correlation of RNFL and macular thickness with serum 
uric acid in type 2 diabetic patients. 
 
Methodology  
A cross-sectional study was conducted in the Eye Clinic, Hospital Universiti Sains Malaysia, 
Kelantan between the period of August 2013 till July 2015 involving type 2 diabetes mellitus 
patients with no diabetic retinopathy and with NPDR. An evaluation for RNFL and macular 
thickness using Spectralis Heidelberg optical coherence tomography was done and 6 mls of 
venous blood was taken for the measurement of serum uric acid and HbA1C. 
 
Results  
A total of 180 diabetic patients were recruited (no diabetic retinopathy: 90 patients and NPDR: 
90 patients) into the study. The mean level of serum uric acid for both the groups were within 
normal range and there was no significance difference between the two groups. The mean level 
of serum uric acid for both gender was significantly higher in no diabetic retinopathy group (p 
= 0.004 respectively). The mean serum uric acid was significantly higher in patient with HbA1C 
< 6.5% (p < 0.031). Patients with NPDR have thicker RNFL and macular thickness compared 
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to patient with no diabetic retinopathy. However, only the RNFL thickness of the temporal 
quadrant and the macular thickness of the superior outer, inferior outer and temporal outer 
subfields were statistically significant (p = 0.038, p = 0.004, 0.033 and <0.001 respectively). 
There was poor correlation between RNFL and macular thickness with serum uric acid in both 
the groups.  
 
Conclusion  
Serum uric acid showed a poor correlation with RNFL and macular thickness among type 2 
diabetic patients. 
 
 
 
 
 
  
 
 
 
 
 
 
CHAPTER 1 
INTRODUCTION 
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1.1 INTRODUCTION 
Retina, is part of the integral component of central nervous system and plays a pivotal role in 
the radial flow of visual signals. The quality of vision deteriorates early in diabetes, before the 
vascular abnormalities becomes evident, probably indicating the early signs of neuronal 
dysfunction. 
 
Diabetic retinopathy is termed as a neurovascular disease which affects both the neuroretinal 
and microvascular component, and the former is said to be compromised early in the course of 
diabetic retinopathy followed by microvascular changes (Stitt et al, 2015). The hallmark of 
retinal neurodegeneration are neural apoptosis and reactive gliosis.  
 
Retinal nerve fibre layer (RNFL) is an important neuronal structure in the retina layer which is 
often shown to be affected in the early pathogenesis of diabetic retinopathy. The functional 
changes that are noticed before the vascular pathology develops are due to direct effect of 
diabetes on the neural retina instead of breakdown of the blood retinal barrier. The retinal 
ganglion cell and glial cells are the major cells in the neuronal component to be compromised 
(Antonetti et al, 2015) reflecting neurodegenerative changes in the diabetic retina with loss of 
neuronal cell bodies and axons (van Dijk et al, 2012). The prominent risk factors for RNFL 
degeneration in a diabetic patient are hyperglycemia, oxidative stress and advanced glycation 
end products. It’s very important to understand the neurodegenerative process of the RNFL as 
it plays a role as an active mediator of the microvascular impairment and used as an index in a 
diabetic patient to predict the development of new microvascular disease in near future. Early 
detection of RNFL thinning allows the ophthalmologist to provide effective treatment, thus 
reducing vision loss. 
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Optical coherence tomography (OCT), has emerged as an excellent non-invasive ocular light-
based imaging modality that can be used in biological system to study tissues in vivo with 
detailed information about the histological changes (Drexler et al, 2008). OCT is widely 
accepted and has been integrated into our everyday clinical practice, has become an essential 
gold standard tool in the diagnosis and monitoring most retinal diseases. 
 
Chronic hyperglycemia contributes to the development and progression of diabetic retinopathy 
and the most important determinants are the disease duration and the degree of glycemic 
control. The HbA1C has been regarded as the gold standard indicator for glycemic control in 
diabetic patients, reflecting the status of the blood glucose control over 3-6 months.  
 
Serum uric acid is a product breakdown of the endogenous and exogenous purine metabolism 
and its derivatives. Increase serum uric acid has been proposed as a biochemical link between 
diabetes and the development of microvascular and macrovascular complications (Goldberg, 
2009). Goldberg (Goldberg, 2009) in his studies have attributed proatherogenic properties of 
uric acid that includes activation of endothelial cells, platelets activation and increase platelet 
adhesiveness which all contribute to the pathogenesis of diabetic retinopathy and other diabetic 
vascular complications. To date, there is still lack of data concerning the role of serum uric acid 
as a predictor in the development and progression of diabetic retinopathy, whether there is any 
significant correlation with RNFL and macular thickness. 
 
This is a cross-sectional study involving patients with no diabetic retinopathy and non-
proliferative diabetic retinopathy (NPDR) among type 2 diabetes mellitus. We evaluated the 
RNFL and macular thickness among both the groups and studied the correlation of RNFL and 
macular thickness with serum uric acid. 
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To the best of our knowledge and following an extensive literature search, there is no studies 
has been published on the correlation of RNFL and macular thickness with serum uric acid 
involving no diabetic retinopathy and NPDR among type 2 diabetes mellitus. This study is the 
first of its kind to be conducted. 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
CHAPTER 2 
OBJECTIVES  
OF THE STUDY 
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2.1   GENERAL OBJECTIVE 
To correlate the RNFL and macular thickness with serum uric acid among type 2 
diabetes mellitus patients with NPDR and without diabetic retinopathy. 
 
2.2  SPECIFIC OBJECTIVES 
i. To determine the correlation between RNFL thickness and serum uric acid among type 
2 diabetes mellitus patients with NPDR. 
ii. To determine the correlation between RNFL thickness and serum uric acid among type 
2 diabetes mellitus patients with no diabetic retinopathy. 
iii. To determine the correlation between macular thickness and serum uric acid among   
type 2 diabetes mellitus patients with NPDR. 
iv. To determine the correlation between macular thickness and serum uric acid among 
type 2 diabetes mellitus patients with no diabetic retinopathy. 
 
 
  
 
 
 
 
 
 
CHAPTER 3 
MANUSCRIPT 
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Correlation of Retinal Nerve Fibre Layer and Macular Thickness with Serum Uric Acid 
among Type 2 Diabetes Mellitus 
3.2 ABSTRACT 
Background 
Serum uric acid is a final breakdown product of purine catabolism in humans. It’s a potent 
antioxidant, that induces oxidative stress on the vascular endothelial cells, thus mediating 
progression of diabetic related diseases. Various epidemiological and experimental evidence 
suggest that uric acid has a role in the etiology of type 2 diabetes mellitus. We conducted a 
cross-sectional study to evaluate the correlation of RNFL and macular thickness with serum 
uric acid in type 2 diabetic patients. 
 
Methods 
A cross-sectional study was conducted in the Eye Clinic, Hospital Universiti Sains Malaysia, 
Kelantan between the period of August 2013 till July 2015 involving type 2 diabetes mellitus 
patients with no diabetic retinopathy and with NPDR. An evaluation for RNFL and macular 
thickness using Spectralis Heidelberg optical coherence tomography was done and 6 mls of 
venous blood was taken for the measurement of serum uric acid and HbA1C. 
 
Results  
A total of 180 diabetic patients were recruited (no diabetic retinopathy: 90 patients and NPDR: 
90 patients) into the study. The mean level of serum uric acid for both the groups were within 
normal range and there was no significance difference between the two groups. The mean level 
of serum uric acid for both gender was significantly higher in no diabetic retinopathy group (p 
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= 0.004 respectively). The mean serum uric acid was significantly higher in patient with HbA1C 
< 6.5% (p < 0.031). Patients with NPDR have thicker RNFL and macular thickness compared 
to patient with no diabetic retinopathy. However, only the RNFL thickness of the temporal 
quadrant and the macular thickness of the superior outer, inferior outer and temporal outer 
subfields were statistically significant (p = 0.038, p = 0.004, 0.033 and <0.001 respectively). 
There was poor correlation between RNFL and macular thickness with serum uric acid in both 
the groups.  
 
Conclusion  
Serum uric acid showed a poor correlation with RNFL and macular thickness among type 2 
diabetic patients. 
 
Keywords 
Diabetic retinopathy; retinal nerve fibre layer thickness; macular thickness; serum uric acid; 
glycosylated haemoglobin. 
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3.3 INTRODUCTION 
 
Diabetes mellitus is regarded as a pandemic, representing one of the most challenging and 
major public health problems of the 21st century. It has become a global alarming disease not 
sparing any country thus posing a serious threat to its economy (1). It has been shown that, 
prevalence of diabetes is rapidly rising and is a major cause of morbidity and mortality (2). 
  
Diabetic retinopathy is the commonest microvascular complication of diabetes mellitus. It 
remains the leading cause of preventable blindness across all age-groups and places a 
significant burden on health services (3). It’s termed as a neurovascular disease which affects 
both the neuroretinal and microvascular component, and the former is said to be compromised 
early in the course of diabetic retinopathy followed by microvascular changes (4). The hallmark 
of retinal neurodegeneration is neural apoptosis of the retinal ganglion cells which are located 
in the inner retina layer and reactive gliosis involving the astrocytes and Muller cells (5). It is 
suggested that the functional changes noticed before the vascular pathology develops are due 
to direct effect of diabetes on the neural retina instead of breakdown of the blood retinal barrier 
(4).  
 
Several studies have used electroretinogram (ERG) on the retinal nerve fibre layer (RNFL). An 
abnormal result suggests early retinal neural dysfunction which in later stages progress to 
neurodegeneration (6,7). It’s also accompanied by deficits in contrast sensitivity, loss of dark 
adaptation and colour vision disturbances (8). Risk factors for RNFL degeneration in a diabetic 
patient are hyperglycemia, oxidative stress and advanced glycation end products (9). Macular 
thickness in the presence of diabetic retinopathy has been shown to be thicker compared to 
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normal population. This is also seen in diabetic patient with no demonstrable evidence of 
retinopathy or macular oedema (10).  
 
Serum uric acid is the product of endogenous and exogenous purine metabolism and its 
derivatives (11). In the purine metabolic pathway (Figure 1), adenosine has vasoactive 
properties that play a role in retinal blood flow. It generates superoxide nitric oxide which affect 
the retinal circulation by causing capillary occlusion, apoptosis of pericytes and basement 
membrane thickening (12). Xanthine, a substrate of xanthine oxidase, enhances superoxide 
generation, causing microvascular dysfunction and exert tissue damage resulting in lipid and 
protein peroxidation (12). This changes are seen in pathogenesis of diabetic retinopathy. 
Various epidemiological and experimental evidence suggest that uric acid has a role in the 
aetiology of type 2 diabetes mellitus (11-13). 
 
From as early as 1950, Griffiths M (14) reported the diabetogenic action of serum uric acid and 
suggested that it’s levels are associated with an increased risk of type 2 diabetic complications. 
Several other studies have also observed similar findings (15,16). Goldberg RB (17), attributed 
proatherogenic properties of serum uric acid to be responsible for the pathogenesis of diabetic 
retinopathy and other diabetic vascular complications. These include activation of endothelial 
cells & platelets and increased platelet adhesiveness. Navin S et al (11) also concluded that 
poor glycemic control in type 2 diabetes mellitus is associated with an increased serum uric 
acid level and dyslipidemia, which could be the initial ongoing biochemical change in the 
complication of diabetes.   
 
In view of numerous evidences suggesting the role of uric acid in diabetic patients, our study 
was conducted to correlate the RNFL thickness and macular thickness with serum uric acid 
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among type 2 diabetes mellitus patients. To the best of our knowledge, there are no studies 
done that correlates serum uric acid with RNFL and macular thickness in diabetic patients. 
 
3.4 MATERIALS and METHODS  
A cross-sectional study was carried out on 180 patients with type 2 diabetic mellitus (no 
diabetic retinopathy: 90 patients and non-proliferative diabetic retinopathy (NPDR): 90 
patients) who attended the Eye Clinic, Hospital Universiti Sains Malaysia, Kelantan, Malaysia 
from August 2013 to July 2015. The study followed the tenets of the declaration of Helsinki 
and was approved by the local ethical board [USM/ JEPeM/ 276.2. (4)].  
 
Type 2 diabetes mellitus patients aged between 40-65 years old with clear media were included. 
Those patients with optic nerve, retina and macular pathology, previous history of laser, history 
of intraocular surgery, renal disease and hyperuricemia were excluded from this study. 
 
The demographic data (patients age, gender and ethnicity) was obtained either from the patient 
or their medical record. A thorough slit lamp and fundus examination was performed by one 
identified ophthalmologist to confirm the diagnosis. The classification of diabetic retinopathy 
was based on the International Diabetic Retinopathy Severity scales (18). Only one eye of the 
worst severity was selected.  
 
This was followed by measurement of the RNFL and macular thickness using the Spectralis-
Domain Optical Coherence Tomography (SD-OCT) (Heidelberg Engineering, Heidelberg, 
Germany).  
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For measurement of RNFL thickness, a 3.45 mm diameter peripapillary ring was measured 
(Figure 2A). All the four quadrants were taken for analysis in this study; superior, inferior, 
temporal and nasal (Figure 2B). The macular thickness was determined by using the ‘6 mm 
fast macular mapping’ scanning pattern. It consists of a high resolution 19 raster line scan 
protocol that was applied on an area centered on the fovea with the horizontal lines spaced 240 
μm apart (Figure 3A). The Early Treatment Diabetic Retinopathy Study (ETDRS) grid was 
applied dividing the macula into 9 subfields, encircled by rings of 1, 3 and 6 mm in diameter. 
All the subfields were taken for analysis in this study: fovea; superior inner, inferior inner, 
temporal inner, nasal inner in the second ring; superior outer, inferior outer, temporal outer and 
nasal outer in the outer ring (Figure 3B).  
 
Six mls of venous blood was drawn from the median cubital vein for measurement of serum 
uric acid and HbA1C. The reference normal range for serum uric acid measured in Hospital 
Universiti Sains Malaysia differs in each gender: Male 180 - 420 µmol/L; Female 150 - 360 
µmol/L.  
 
The statistical analysis was carried out using Statistical Package for Social Sciences (SPSS) 
Version 22. All values were tested for normal distribution and equal variances. Chi Square test 
was used for comparison of gender and ethnicity. Independent t-test was used for comparison 
of age, HbA1C, serum uric acid, RNFL thickness and macular thickness.  Significance of 
difference in values was determined by the ‘p’ value < 0.05. The correlation between RNFL 
thickness and macular thickness with serum uric acid was tested using Pearson correlation. 
Significance of correlation was decided based on ‘r’ (19) and ‘p’ values.  
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3.5 RESULTS 
Demographic Data 
The distribution of demographic data is shown in Table 1. The male and female gender were 
not equally distributed among both groups, and statistically not significant (p = 0.101). The 
percentage of male was higher in no diabetic retinopathy and vice versa in NPDR. 
 
Majority of the patients were Malay in both the groups, 73% with no diabetic retinopathy and 
75% with NPDR. There was no statistically significant difference among the ethnicity (p = 
0.138). 
 
Both the groups showed a poor diabetic control with mean HbA1C more than 6.5%. The HbA1C 
was significantly higher in NPDR (9.59%, SD 2.27) compared to no diabetic retinopathy 
(7.84%, SD 2.01) (p < 0.001). 
 
Serum Uric Acid 
The mean level of serum uric acid for both the groups were within normal range but at the 
upper limit. There was no statistically significant difference between the groups (p = 0.220) 
(Table 2). However, based on gender, diabetic patients with no diabetic retinopathy showed a 
significantly higher level of mean serum uric acid compared to those in NPDR group (p = 0.004 
respectively). Generally, the male gender had a higher mean serum uric acid level compared to 
female gender in both the groups. 
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The mean level of serum uric acid was significantly higher in those patient with HbA1c < 6.5% 
compared to those with HbA1c ≥ 6.5% (p = 0.031) (Table 3). 
 
Retinal Nerve Fibre Layer and Macular Thickness 
Patients with NPDR generally have thicker RNFL and macular thickness compared to patient 
with no diabetic retinopathy. However, only the RNFL thickness of the temporal quadrant and 
the macular thickness of the superior outer, inferior outer and temporal outer subfields were 
statistically significant (p = 0.038, p = 0.004, 0.033 and <0.001 respectively) (Table 4). 
 
Correlation between RNFL Thickness and Serum Uric Acid 
The RNFL thickness showed a poor negative correlation with serum uric acid in all the 
quadrants for both the groups except the RNFL thickness of the temporal quadrant of no 
diabetic retinopathy group showed a poor positive correlation (Table 5). 
 
Correlation between Macular Thickness and Serum Uric Acid  
All the macular subfields in the no diabetic retinopathy group showed a poor negative 
correlation with serum uric acid except the fovea subfield showed poor positive correlation. 
Whereas, all the macular subfields in the NPDR group showed a poor positive correlation 
except superior outer subfield showed a poor negative correlation (Table 5). 
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3.6 DISCUSSION 
 
Serum uric acid is a final breakdown product of purine catabolism in humans. It’s a potent 
antioxidant, that induces oxidative stress on the vascular endothelial cells, thus mediating 
progression of diabetic related diseases (20). Various epidemiological and experimental 
evidence suggest that uric acid has a role in the etiology of type 2 diabetes mellitus (11-13). 
We conducted a cross-sectional study to evaluate the correlation of RNFL and macular 
thickness with serum uric acid in type 2 diabetic patients. 
 
The mean age of our study participants ranged between 51 to 52 years old. This was fairly 
consistent with several other studies (21,22). In contrast, Eydis Olafsdottir et al (23) showed 
the prevalence of no diabetic retinopathy and those with retinopathy in diabetic patients was 
slightly in the older age group. However, Hansson-Lundblad et al. (24), reported there is no 
association between age and retinopathy. Perhaps, duration of diabetes, is an independent risk 
factor for occurrence of retinopathy (21,23). Both the gender was not equally distributed in our 
study. This was similar to previous studies that reported no significant differences between 
retinopathy and gender (21,25). 
 
The majority of the participants in our study were Malay. Malaysia has a multiethnic population 
with three main races; Malay, Chinese and Indian. However, Kelantan is a predominantly 
Malay village in the north-eastern state of the Peninsular. This perhaps explains the 
preponderance of Malay participants in our study. From our findings, the NPDR group had 
poor glycemic control. This was similar to other studies done at various places (26,27). 
 
There are several studies that have linked serum uric acid with the pathogenesis and 
progression of diabetic retinopathy (13,28). In our study, total serum uric acid was higher in 
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no diabetic retinopathy group, but not statistically significant. The serum uric acid was 
significantly higher in patients with HbaA1C < 6.5%. This in accordance with previous studies 
that stated elevated serum uric acid levels during the early stage of impaired glucose 
metabolism is said to predict the onset of the type 2 diabetes and has been linked to both micro 
and macrovascular complications (29,30). Bonakdaran S et al (31), noted a significant 
correlation between hyperuricemia and HbA1C. Dehghan A et al (16) reported high serum uric 
acid level precedes hyperinsulinemia and diabetes inducing endothelial dysfunction and 
oxidative stress. 
 
Two studies involving type 2 diabetic patients were conducted in China, showed serum uric 
acid levels correspond to the severity of diabetic retinopathy (32,33). The serum uric acid level 
was showed to increase gradually with increase of severity of diabetic retinopathy. Causevic A 
et al (34) reported that the serum uric acid level was increased in type 2 diabetes mellitus and 
associated with insulin resistant syndrome. Moreover, Ashakiran S. et al (35), noticed that the 
compensatory hyperinsulinemia (insulin resistant) showed an antiuricosuric effect on the 
kidneys which lead to increase serum uric acid level.  
 
In contrast, Nan H et al (36) mentioned that the serum uric acid and fasting plasma glucose 
level increases in non-diabetic individuals but showed lower level in diabetic patient. However, 
Olukoga AO et al (37) and Segato T et al (38), reported no significant association between 
serum uric acid and diabetic retinopathy. Pfister R et al (39), tested eight common genetic 
variants which were identified as determinant of serum uric acid level on diabetic patients 
involving a large cohort of European descent. Their results do not support the association of 
serum uric acid in the development of type 2 diabetes mellitus.  
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The male gender had higher level of serum uric acid compared to the female gender. We also 
observed, the mean serum uric acid in both the gender were statistically significant in no 
diabetic retinopathy than in NPDR. Our findings were in parallel to another study that showed 
serum uric acid level was much higher in male than female (40). Evidence regarding estrogen 
promotes uric acid excretion (41) supports the findings of hyperuricemia among the males. 
Choi H.K et al (41), reported that serum uric acid was significantly higher in diabetic male than 
female. However, this sex predilection it’s still controversial. In contrary Causevic A et al (34), 
demonstrated there is no effect of gender on serum uric acid levels in diabetic patient.  
 
As we know, there are various studies that regards diabetic retinopathy as a neurovascular 
disease whereby the retinal neurodegeneration antedates the microvascular abnormalities 
(4,42). The retinal nerve fibre loss was contributed by retinal ganglion cell death and axonal 
degeneration. In our study, the mean RNFL thickness in all the 4 quadrants were thinner in no 
diabetic retinopathy compared to NPDR. Only the temporal quadrant was statistically 
significant. Our findings were parallel to some studies (26,42) and in contrast to few other 
studies (43,44). All 9 subfields of the macular region showed similar changes as the RNFL. 
However, only 3 subfields were statistically significant (superior outer, inferior outer and 
temporal outer). These results of our studies were consistent to some studies (13,45) and 
contradictory to few other studies (46,47).  
 
Several studies, including ours, showed presence of neuronal abnormalities at the early stage 
of diabetes irrespective of the type of OCT used (25,48-49). This explains the thinner retina in 
no diabetic retinopathy and the increase vascular permeability leads to increased retinal 
thickness. In our study, we have pooled all severity of NPDR grades, gender and age. Similar 
to findings found by other studies (25,49), our study made an assumption that increase in the 
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retinal thickening observed in the NPDR group was due to the insult from hard exudates and 
retinal hemorrhages leading to accumulation of intra-retinal fluids. This subsequently results 
in an increased thickness of the RNFL. Although we have excluded patients with clinically 
apparent and extensive retinal oedema, a possible presence of subclinical retinal oedema in our 
diabetic patients can interfere the OCT measurement. Subclinical macular oedema in which 
clinically shows absence of macular oedema on slit lamp examination but on OCT shows 
abnormally increased macular thickness (49). 
 
We found that only the temporal RNFL quadrant showed a mean significant difference. The 
superior RNFL quadrant also showed a change in the retinal thickness between the no diabetic 
retinopathy and NPDR groups however it was not significant. The inferior RNFL quadrant 
showed a minimal change which is almost negligible between the two groups. In the macular 
thickness, only the outer most ring including the superior, temporal and inferior subfield 
showed a significant difference.  There are several studies that observed the superior and 
temporal quadrants to be thinner than the inferior quadrants (50,51) showing that the early 
events of diabetic retinal disease (microaneurysms and acellular capillaries) occur 
preferentially in the superior temporal quadrant rather than in inferior areas. Chung et al (52) 
demonstrated that blood flow in the superior temporal retina increased in response to 
hypercapnia, but did not decrease in response to hyperoxia. In contrast, hyperoxia led to a 
decrease in blood flow to the inferior retina, whereas hypercapnia did not result in an increased 
blood flow within this area (52). The lack of normal vasoconstrictor response in this superior 
quadrant could explain why this region is more susceptible to micro aneurysms and acellular 
capillaries in diabetes mellitus and also why the retinal fibres are preferentially lost in this 
region even before clinically detectable diabetic retinopathy (53). The superior quadrant was 
more susceptible to undergoing damage compared with other areas and may have a tendency 
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for higher rates of cell death, which results in RNFL thinning (26). We also noticed that the 
thickest RNFL in nasal quadrant might be due to the lack of micro aneurysm presence in this 
area and therefore less RNFL damage occurred in this quadrant. We assume the differences in 
the vascular hemodynamics in the macular region might be also the contributing factors to 
these phenomena of asymmetrical retinal thickness.  
 
Serum uric acid pathogenesis, has been associated with the development and worsening of the 
diabetic retinopathy (31). Chien KL et al (54) and Ishizaka N et al (55), suggested that increase 
level of serum uric acid acts as a predictor for diabetic vascular complications. Oxidative stress 
is a culprit for the progression of diabetic retinopathy (29). Serum uric acid conversely can act 
as an antioxidant (31). However, Jianfei Xia et al (56) demonstrated that there was significantly 
increased concentration of uric acid among diabetic patients and serum uric acid might be a 
risk factor for diabetic retinopathy. High serum uric acid level was said as a risk factor of type 
2 diabetes mellitus. Lowering the serum uric acid with xanthine oxidase inhibitors can reduce 
the incidence of type 2 diabetes mellitus and its complication but this is still controversial. Anju 
G et al (57) in her studies concluded that serum uric acid levels increase in newly diagnosed 
diabetic patients, thus it can serve as potential biomarker of the glucose metabolism. 
 
We did a correlation between the serum uric acid with RNFL thickness and macular thickness 
among no diabetic retinopathy and NPDR. Based on our Medline research, our study is the first 
study to be conducted. Uric acid inspite being an antioxidant in the circulation, it induces 
oxidative stress in the vascular endothelial cells, thus mediating progression of disease related 
to diabetic. Oxidative stress is believed to play an important role in the development of vascular 
complications in type 2 diabetes mellitus (21).   
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From our study, we did not find any momentous correlation between the RNFL and macular 
thickness with serum uric acid in both the groups. However, in patient with no diabetic 
retinopathy, only the inferior outer macular subfield which had poor negative correlation with 
serum uric acid showed a statistically significant relationship. This negative relationship 
indicates that the higher serum uric acid level, the patient is likely to have minimal thinning of 
the macular region but the relationship is at a lower rate. This has to be interpreted cautiously 
as only one macular subfield showed a significant relationship. From our findings, we postulate 
that, in no diabetic retinopathy group, the serum uric acid level is higher which is said to 
precede the type 2 diabetes, and inversely causes thinning of the macular region secondary to 
retinal neurodegeneration.  
 
In patient with NPDR, only the central subfield and inferior inner macula showed a fair positive 
correlation with a significant relationship. This positive significant relationship indicates that 
the higher serum uric acid level, the patient is likely to have thicker macular but the relationship 
is at a lower rate. From our findings, we postulate that, in NPDR group, there will be high 
likely for nephropathy to set in, thus affecting the renal excretion, increases rates of renal 
reabsorption, increases the excretion of purine metabolism subsequently raises the production 
of uric acid. The increase in serum uric acid level via the inflammatory process results in 
progression of diabetic vascular complication, thus causing vascular leakage and indirectly 
causing an impact to the macular thickness especially in the posterior pole. 
 
There are several limitations found in our studies. The pooling of the severity of NPDR would 
have led to potential spurious comparisons. Other limitations include not taking into account 
the duration of diabetes, no follow up given, distribution of race and gender were not equal. 
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We also did not include parameters for kidney dysfunction or diabetic nephropathy that could 
alter the excretion of uric acid. 
 
3.7 CONCLUSION 
Serum uric acid showed a poor correlation with RNFL and macular thickness among diabetic 
patients. A large population cohort study with well distributed ethnicity and gender is needed 
to observe if there is presence of correlation between serum uric acid with RNFL and macular 
thickness among type 2 diabetic patients. 
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